Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2007. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 117,500 ordinary shares.
- Price per Share: 1,319.8511 pence.
- Treasury Shares Held: 504,194,158 shares (representing 9.15% of total voting rights).
- Shares in Issue: 5,507,831,537 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 117,500 shares purchased on December 13, 2007. Consequently, the total number of shares in issue remains 5,507,831,537, while the Treasury share count stands at 504,194,158.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,507,831,537) for calculating ownership percentages under Disclosure Transparency Rules.
- Confirm the Treasury share holding of 504,194,158 shares, which represents 9.15% of total voting rights.
- Note that this filing is a notification of a specific share buyback event and does not contain periodic financial performance data.